Enhancing tumor specific immune responses by transcutaneous vaccination

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Expert Review of Vaccines

• Publication date

  2017-10-17

• Fields of study

  Medicine

• Identifiers
  DOI 10.1080/14760584.2017.1382357PMID 28937293
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• DNA vaccination for cervical cancer; a novel technology platform of RALA mediated gene delivery via polymeric microneedles.

  2017cited by this paper
• Dissolving Microneedle Arrays for Transdermal Delivery of Amphiphilic Vaccines.

  2017cited by this paper
• Do nanoparticles have a future in dermal drug delivery?

  2017cited by this paper
• Recent Advances in Lipid-Based Vesicles and Particulate Carriers for Topical and Transdermal Application.

  2017cited by this paper
• A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.

  2016cited by this paper
• Liposomal constructs for antitumoral vaccination by the nasal route.

  2016cited by this paper
• Evaluation of microparticulate ovarian cancer vaccine via transdermal route of delivery.

  2016cited by this paper
• Chemical penetration enhancers in stratum corneum - Relation between molecular effects and barrier function.

  2016cited by this paper
• Vaccination with liposome-coupled glypican-3-derived epitope peptide stimulates cytotoxic T lymphocytes and inhibits GPC3-expressing tumor growth in mice.

  2016cited by this paper
• Transdermal immunization of P. falciparum surface antigen (MSP-119) via elastic liposomes confers robust immunogenicity

  2016cited by this paper
• Adjuvants for peptide-based cancer vaccines

  2016influential reference
• Differential activation behavior of dermal dendritic cells underlies the strain-specific Th1 responses to single epicutaneous immunization.

  2016cited by this paper
• Tetanus vaccination with a dissolving microneedle patch confers protective immune responses in pregnancy.

  2016cited by this paper
• Topical Delivery of Protein and Peptide Using Novel Cell Penetrating Peptide IMT-P8

  2016cited by this paper
• Tecemotide in unresectable stage III non-small-cell lung cancer in the phase III START study: updated overall survival and biomarker analyses.

  2015cited by this paper
• Recent insights into cutaneous immunization: How to vaccinate via the skin.

  2015cited by this paper
• Nanoparticle Drug Delivery Systems Designed to Improve Cancer Vaccines and Immunotherapy

  2015cited by this paper
• NY‐ESO‐1 specific antibody and cellular responses in melanoma patients primed with NY‐ESO‐1 protein in ISCOMATRIX and boosted with recombinant NY‐ESO‐1 fowlpox virus

  2015cited by this paper
• Nanoparticles skin absorption: New aspects for a safety profile evaluation.

  2015cited by this paper
• Airway administration of a highly versatile peptide-based liposomal construct for local and distant antitumoral vaccination.

  2015cited by this paper
• Hair follicle targeting, penetration enhancement and Langerhans cell activation make cyanoacrylate skin surface stripping a promising delivery technique for transcutaneous immunization with large molecules and particle‐based vaccines

  2015cited by this paper
• Development, characterization, and skin delivery studies of related ultradeformable vesicles: transfersomes, ethosomes, and transethosomes

  2015cited by this paper
• From mice to humans: developments in cancer immunoediting.

  2015influential reference
• Resiquimod as an Immunologic Adjuvant for NY-ESO-1 Protein Vaccination in Patients with High-Risk Melanoma

  2015cited by this paper
• Interactions of hyaluronic Acid with the skin and implications for the dermal delivery of biomacromolecules.

  2015cited by this paper
• A highlight on lipid based nanocarriers for transcutaneous immunization.

  2015cited by this paper
• P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer.

  2014cited by this paper
• Tecemotide: An antigen-specific cancer immunotherapy

  2014cited by this paper
• Liposomes as vaccine delivery systems: a review of the recent advances

  2014cited by this paper
• Distinct behavior of human Langerhans cells and inflammatory dendritic epidermal cells at tight junctions in patients with atopic dermatitis.

  2014cited by this paper
• Induction of cytotoxic T cells as a novel independent survival factor in malignant melanoma with percutaneous peptide immunization.

  2014cited by this paper
• Enhancing Efficacy of Anticancer Vaccines by Targeted Delivery to Tumor-Draining Lymph Nodes

  2014cited by this paper
• Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial.

  2014cited by this paper
• Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205

  2014cited by this paper
• Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance

  2014cited by this paper
• Development of novel topical drug delivery system containing cisplatin and imiquimod for dual therapy in cutaneous epithelial malignancy

  2014cited by this paper
• Murine Langerin+ dermal dendritic cells prime CD8+ T cells while Langerhans cells induce cross-tolerance

  2014cited by this paper
• Parameter optimization toward optimal microneedle-based dermal vaccination.

  2014cited by this paper
• Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells.

  2013cited by this paper
• Transcutaneous antigen delivery system

  2013cited by this paper
• Development of liposomal formulations: From concept to clinical investigations

  2013cited by this paper
• Frontiers of transcutaneous vaccination systems: Novel technologies and devices for vaccine delivery

  2013cited by this paper
• Head-to-head comparison of an intradermal and a virosome influenza vaccine in patients over the age of 60

  2013cited by this paper
• First-inman application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian , breast and prostate cancer patients

  2012cited by this paper
• A novel vesicular carrier, transethosome, for enhanced skin delivery of voriconazole: characterization and in vitro/in vivo evaluation.

  2012cited by this paper
• Skin Langerin+ Dendritic Cells Transport Intradermally Injected Anti–DEC-205 Antibodies but Are Not Essential for Subsequent Cytotoxic CD8+ T Cell Responses

  2012cited by this paper
• First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

  2012cited by this paper
• Comparative study of liposomes, transfersomes, ethosomes and cubosomes for transcutaneous immunisation: characterisation and in vitro skin penetration

  2012cited by this paper
• Transcutaneous DNA immunization following waxing-based hair depilation.

  2012cited by this paper
• Identification of a novel skin penetration enhancement peptide by phage display peptide library screening.

  2012cited by this paper
• Human hair follicle: reservoir function and selective targeting

  2011cited by this paper
• Langerhans cell antigen capture through tight junctions confers preemptive immunity in experimental staphylococcal scalded skin syndrome

  2011cited by this paper
• Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting.

  2011cited by this paper
• Immunoediting and persistence of antigen-specific immunity in patients who have previously been vaccinated with NY-ESO-1 protein formulated in ISCOMATRIX™

  2011cited by this paper
• T cell exhaustion

  2011cited by this paper
• Microsecond thermal ablation of skin for transdermal drug delivery.

  2011cited by this paper
• Langerhans cells are negative regulators of the anti-Leishmania response

  2011cited by this paper
• Hair follicles contribute significantly to penetration through human skin only at times soon after application as a solvent deposited solid in man.

  2011cited by this paper
• Transcutaneous and intradermal vaccination

  2011influential reference
• Enabling skin vaccination using new delivery technologies

  2011cited by this paper
• Selective follicular targeting by modification of the particle sizes.

  2011cited by this paper
• Targeting to the hair follicles: current status and potential.

  2010cited by this paper
• CD207+ CD103+ dermal dendritic cells cross-present keratinocyte-derived antigens irrespective of the presence of Langerhans cells

  2010influential reference
• Surface charged temoporfin-loaded flexible vesicles: in vitro skin penetration studies and stability.

  2010cited by this paper
• Epidermal Langerhans cells rapidly capture and present antigens from C-type lectin-targeting antibodies deposited in the dermis.

  2010cited by this paper
• Acute Ablation of Langerhans Cells Enhances Skin Immune Responses

  2010cited by this paper
• A liposome-based platform, VacciMax, and its modified water-free platform DepoVax enhance efficacy of in vivo nucleic acid delivery.

  2010cited by this paper
• Regulatory T-Cell–Mediated Attenuation of T-Cell Responses to the NY-ESO-1 ISCOMATRIX Vaccine in Patients with Advanced Malignant Melanoma

  2009cited by this paper
• Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells

  2009cited by this paper
• Influence of ligand valency on the targeting of immature human dendritic cells by mannosylated liposomes.

  2008cited by this paper
• Controlled, single-step, stratum corneum disruption as a pretreatment for immunization via a patch.

  2008cited by this paper
• Insights into Langerhans cell function from Langerhans cell ablation models

  2008cited by this paper
• Cutting Edge: Langerin/CD207 Receptor on Dendritic Cells Mediates Efficient Antigen Presentation on MHC I and II Products In Vivo1

  2008cited by this paper
• Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant1

  2008cited by this paper
• Lipid vesicles for skin delivery of drugs: reviewing three decades of research.

  2007cited by this paper
• Strong cellular and humoral immune responses induced by transcutaneous immunization with HBsAg DNA–cationic deformable liposome complex

  2007cited by this paper
• Type 1 and 2 immunity following vaccination is influenced by nanoparticle size: formulation of a model vaccine for respiratory syncytial virus.

  2007cited by this paper
• Differential Antigen Processing by Dendritic Cell Subsets in Vivo

  2007cited by this paper
• Exploiting lymphatic transport and complement activation in nanoparticle vaccines

  2007cited by this paper
• Both Langerhans cells and interstitial DC cross‐present melanoma antigens and efficiently activate antigen‐specific CTL

  2007influential reference
• Safety and Immunogenicity of an Enterotoxigenic Escherichia coli Vaccine Patch Containing Heat-Labile Toxin: Use of Skin Pretreatment To Disrupt the Stratum Corneum

  2007cited by this paper
• The cell-penetrating peptide TAT(48-60) induces a non-lamellar phase in DMPC membranes.

  2006cited by this paper
• Langerhans cells cross-present antigen derived from skin

  2006cited by this paper
• Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX® vaccine in advanced-stage non-small-cell lung cancer

  2006cited by this paper
• 40 nm, but not 750 or 1,500 nm, nanoparticles enter epidermal CD1a+ cells after transcutaneous application on human skin.

  2006cited by this paper
• Stable cationic microparticles for enhanced model antigen delivery to dendritic cells.

  2006cited by this paper
• Behavioral responses of epidermal Langerhans cells in situ to local pathological stimuli.

  2006cited by this paper
• Pathogen recognition and development of particulate vaccines: does size matter?

  2006cited by this paper
• In vivo targeting of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles.

  2006cited by this paper
• Transfersomes for transdermal drug delivery

  2006cited by this paper
• Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model.

  2005cited by this paper
• Dynamics and function of Langerhans cells in vivo: dermal dendritic cells colonize lymph node areas distinct from slower migrating Langerhans cells.

  2005cited by this paper
• Potential use of nanoparticles for transcutaneous vaccine delivery: effect of particle size and charge.

  2004cited by this paper
• Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4(+) and CD8(+) T cell responses in humans.

  2004cited by this paper
• Immune surveillance in the skin: mechanisms and clinical consequences

  2004cited by this paper
• Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1

  2004cited by this paper
• Expression of C-type lectin receptors by subsets of dendritic cells in human skin.

  2004cited by this paper
• CD8α‐ and Langerin‐negative dendritic cells, but not Langerhans cells, act as principal antigen‐presenting cells in leishmaniasis

  2004cited by this paper
• Cancer immunoediting: from immunosurveillance to tumor escape

  2002cited by this paper
• The mannose receptor family.

  2002cited by this paper

• Evaluating Cancer Risks: The Impact of Thirdhand Smoke Exposure on Carcinogenesis.

  2025cites this paper
• Anamnestic response against bovine viral diarrhea virus and bovine herpesvirus type 1 in young Holstein heifers vaccinated with four different commercial formulations

  2024cites this paper
• Noninvasive Transdermal Administration of mRNA Vaccines Encoding Multivalent Neoantigens Effectively Inhibits Melanoma Growth.

  2024cites this paper
• Delivery of mRNA vaccines and anti-PDL1 siRNA through non-invasive transcutaneous route effectively inhibits tumor growth

  2022cites this paper
• Nanovaccine for transdermal delivery system

  2021cites this paper
• Formulation‐based approaches for dermal delivery of vaccines and therapeutic nucleic acids: Recent advances and future perspectives

  2021cites this paper
• Separable double-layered microneedle-based transdermal codelivery of DOX and LPS for synergistic immunochemotherapy of a subcutaneous glioma tumor

  2021cites this paper
• Combination of Microneedles and MF59 Adjuvant as a Simple Approach to Enhance Transcutaneous Immunization.

  2020cites this paper
• Highly potent intradermal vaccination by an array of dissolving microneedle polypeptide cocktails for cancer immunotherapy.

  2020cites this paper
• Molecular cloning, characterization and expression profiles of Annexin family (ANXA1∼A6) in yellow catfish (Pelteobagrus fulvidraco) and ANX regulation by CpG ODN responding to bacterial infection.

  2020cites this paper
• Current Progress in Particle-Based Systems for Transdermal Vaccine Delivery

  2020cites this paper
• Advances in non and minimal-invasive transcutaneous delivery of immunotherapy for cancer treatment.

  2020cites this paper
• Transcutaneous delivery of DNA/mRNA for cancer therapeutic vaccination

  2019cites this paper
• Serological response against bovine herpesvirus and bovine viral diarrhea virus induced by commercial vaccines in Holstein heifers

  2019cites this paper
• Созревание in vitro дендритных клеток здоровых лиц и пациентов с хроническим остеомиелитом, вызванным Staphylococcus aureus

  2019cites this paper
• Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets

  2019cites this paper